A shocking new approval from the FDA has ignited outrage among staunch defenders of life. This decision, greenlighting a generic version of mifepristone—used in over 60% of abortions—stands in direct contradiction to the Trump administration’s pro-life principles.
The bold critique comes from 13 House Republicans, spearheaded by Congressman Mark Harris of North Carolina. They are calling for decisive accountability from Health and Human Services Secretary Robert F. Kennedy Jr. The lawmakers assert that “rogue actors” within the FDA have undermined the administration’s commitment to protecting life.
“The approval of this dangerous drug not only contravenes the announced review but also contradicts our pro-life agenda,” they declared. The message is clear: those responsible for this reckless decision must be held accountable.
Harris insists that the administration must act swiftly. “For this reason, we respectfully urge that you consider the director of the Office of Generic Drugs, the director of the Center for Drug Evaluation and Research, and other bureaucrats responsible for this reckless decision as part of your reduction-in-force evaluations,” he stated emphatically.
Joining Harris are strong voices from across the Republican spectrum, including Reps. Josh Brecheen, Keith Self, Eli Crane, Paul Gosar, Chip Roy, Mary Miller, Andy Biggs, Barry Moore, Scott Perry, Ralph Norman, Sheri Biggs, and Ben Cline, all united in this call to action.
Mifepristone operates by depriving an unborn child of essential nutrients, ultimately leading to its demise. This horrific process is completed by another drug that induces labor, forcing the mother to expel her deceased baby—a tragedy that pro-life advocates refuse to accept.
To remove those at the helm of this approval would send a clear message: the administration stands firm in its defense of innocent life. “As stewards of the taxpayers’ trust and defenders of the unborn, we must ensure that no federal office operates in open defiance of our values,” Harris asserted. This moment is critical for demonstrating that the lives of the unborn, and the health of women, are not subject to bureaucratic mismanagement or ideological agendas.
In response to the backlash, Health and Human Services Communications Director Andrew Nixon downplayed the situation, asserting that the FDA’s discretion in approving generic drugs is minimal. He stated that by law, the Secretary of Health must approve any application that proves to be identical to the brand-name drug. However, this explanation falls short of addressing the ethical implications of approving a drug tied to such grave consequences.
Only two other companies, Danco Labs and Genbiopro, had previously been authorized to distribute this life-ending drug. The FDA’s recent communication to Evita Solutions confirmed that it concluded adequate information was provided to justify approval—a move that has left pro-life advocates reeling and invigorated in their quest for stricter regulations on the distribution of abortion pills nationwide.
The time has come to stand firm and restore the integrity of life in our policies. This administration must not shy away from its pro-life commitments. It is time to send a resounding message: the lives of the unborn matter, and we will not tolerate ideological encroachments that threaten their existence.
